Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.